Diabetes drugs now represent over 75% of total sales in the metabolic disorders market, up from below 40% ten years ago. The ...
Pharmaceutical stalwart Novo Nordisk (NVO) can’t seem to get anything good going these days. As TipRanks’ Vince Condarcuri ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...
Imagine if you could eat your fill on Christmas day then dial down your appetite for January. Good news: such a prospect may ...
Biopharmaceutical firms engaged in developing weight-loss drugs were rewarded rather significantly in 2024. It’s what helped ...
We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on Kontra Investments’ Substack by Kontra. In this article, we ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
It hasn’t been a smooth year for the two pharma giants, but events in the fourth quarter widened the gap between them.
In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...
A new technology is disrupting the economy. Even experts don’t entirely understand how it works, its full range of uses and ...
Given Wegovy’s success and record-high sales, a wave of investments has gone into the obesity space over the last couple of ...
In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish company’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback